Related Experiment Video

Updated: May 31, 2025

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.0K

Immunotherapy in Oncogene-Addicted NSCLC: Evidence and Therapeutic Approaches

Lorenzo Foffano1,2, Elisa Bertoli1, Martina Bortolot1,2

  • 1Department of Medical Oncology, CRO di Aviano, National Cancer Institute, IRCCS, 33081 Aviano, Italy.

International Journal of Molecular Sciences
|January 25, 2025
PubMed

Insights

Immune checkpoint inhibitors (ICIs) show limited success in non-small cell lung cancer (NSCLC) with driver mutations. This review explores strategies to improve ICI efficacy in these patients, focusing on personalized immunotherapy approaches.

Area of Science:

  • Oncology
  • Immunotherapy
  • Genetics

Background:

  • Non-small cell lung cancer (NSCLC) is a major global cancer mortality cause.
  • Targeted therapies have improved outcomes for oncogene-addicted NSCLC.
  • Immune checkpoint inhibitors (ICIs) have shown limited efficacy in this patient group.

Purpose of the Study:

  • To review the current evidence on immunotherapy efficacy in oncogene-addicted NSCLC.
  • To analyze factors influencing ICI effectiveness in different driver mutation subgroups.
  • To explore strategies for optimizing immunotherapy in NSCLC treatment algorithms.

Main Methods:

  • Comprehensive literature review of clinical trials and preclinical studies.
  • Analysis of mechanisms potentially reducing immunotherapy efficacy.
  • Examination of evidence on immunotherapy combinations.

Main Results:

  • Significant heterogeneity exists in immunotherapy response across NSCLC driver mutation subgroups.
  • Certain patient subsets may benefit from ICIs, especially with combined therapies.
  • Understanding resistance mechanisms is crucial for improving outcomes.

Conclusions:

  • Personalized immunotherapy strategies are needed for oncogene-addicted NSCLC.
  • Combining ICIs with other modalities may enhance efficacy.
  • Further research is required to optimize immunotherapy integration into NSCLC treatment.
Keywords:
immunotherapynew therapeutic strategiesoncogene-addicted non-small cell lung cancertreatment resistance

More Related Videos

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer07:55

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer

Published on: January 17, 2025

633
Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

8.8K

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
466
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.4K
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.5K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
330
Gene Therapy00:59

Gene Therapy

Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be...
25.1K